对中度至重度克罗恩病治疗序列的成本效益分析
Matthijs M Versteegh1, Simone A Huygens2, Inigo Bermejo3
1Department of Research, Development and Medicines, Dutch Health Care Institute, Willem Dudokhof 1, Diemen, The Netherlands. mversteegh@zinl.nl.
对于中度至重度的克罗恩病 (CD) 最具成本效益的治疗顺序包括开始用阿扎西奥普林/ 甲酸盐,然后再进行组合治疗. 这种方法优化了长期的效益和成本,改善了临床指南的制定.
科学领域:
- 药物经济学
- 胃肠病学
- 医疗技术评估
背景情况:
- 中度至重度的克罗恩病 (CD) 管理涉及复杂的顺序治疗,最佳的顺序具有挑战性的临床实践.
- 目前的成本效益分析往往无法捕捉顺序治疗的有效性和现实数据.
研究的目的:
- 为克罗恩病治疗序列开发先进的成本效益模型.
- 整合网络元分析 (NMA) 疗效数据与注册表数据进行长期预测.
主要方法:
- 创建了一个个体状态过渡模型,包含四个健康状态和五个顺序治疗线.
- 结合了NMA (生物原始和暴露) 和荷兰注册数据的疗效数据.
- 分析采用了荷兰的社会视角,包括终身期,折扣成本和QALY.
主要成果:
- 最具成本效益的升级序列开始于阿扎西奥普林/ 甲酸盐,其次是联合治疗 (infliximab + azathioprine).
- 最具成本效益的上下序列是通过联合治疗 (infliximab + azathioprine) 开始的.
- 需要大幅降低乌斯特基努马布的价格,以使其与抗TNF组合治疗的成本效益相匹配.
结论:
- 整合NMA和注册表数据可以提高CD处理序列的成本效益模型.
- 开发的开源模型可用于更新新疗法,帮助临床指南和药物评估.
更多相关视频
06:28E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
Published on: August 1, 2019
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
